Is Emergent BioSolutions Stock a Buy?

If you had invested $10,000 in shares of Emergent BioSolutions (NYSE: EBS) at the beginning of last year, that investment would be worth $16,608 as of Dec. 31. That's an impressive outperformance compared to the S&P 500's 18.4% return last year. And the stock is likely to surge to a new all-time high in 2021 for one key reason. 

Emergent BioSolutions has managed to secure manufacturing deals with several prominent coronavirus vaccine drugmakers on top of marketing several critical public health products. These agreements could potentially add over $1 billion in future revenue for a company that has a market cap of only $4.75 billion. Let's look at why the company is a top coronavirus stock to buy right now.

Image source: Getty Images.

Continue reading

Source Fool.com